Comparing two repeat ablation approaches for atrial fibrillation using pulsed-field energy
Compares two repeat heart ablation methods in adults with atrial fibrillation.
Plain-language title generated from the registry record
Registry title: Redo-Pulmonary Vein Isolation With Versus Without Posterior Wall Ablation - The REDO-PIFPAF-PFA Study
Key facts
- Where
- Basel, Bern, Lausanne, Sankt Gallen, and Zurich, SwitzerlandSee the 5 sites
Where in Switzerland
- University Hospital BaselBasel, SwitzerlandNo longer taking part
- Bern University HospitalBern, SwitzerlandNo longer taking part
- University Hospital LausanneLausanne, SwitzerlandNo longer taking part
- Cantonal Hospital of St. GallenSankt Gallen, SwitzerlandNo longer taking part
- University Hospital ZurichZurich, SwitzerlandNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University Hospital, Basel, Switzerland
- Trial code
- NCT07745543
- Record updated
- 4 August 2026
- Original description
The study will compare two ablation strategies in patients with paroxysmal or persistent atrial fibrillation undergoing repeat ablation using pulsed-field ablation: redo pulmonary vein isolation only versus redo pulmonary vein isolation with added posterior wall ablation.Read full original descriptionShow less
Redo-Pulmonary Vein Isolation Using Pulsed-Field Ablation With Versus Without Posterior Wall Ablation in Patients With Symptomatic Atrial Fibrillation: A Multi-Centre Randomized Clinical Trial: The REDO-PIFPAF-PFA Study
The study will compare two ablation strategies in patients with paroxysmal or persistent atrial fibrillation undergoing repeat ablation using pulsed-field ablation: redo pulmonary vein isolation only versus redo pulmonary vein isolation with added posterior wall ablation.
Inclusion: Documented recurrence of paroxysmal or persistent AF following single prior catheter ablation with PVI, confirmed by 12-lead ECG, Holter monitoring, or ICM within the last 2 years; Candidate for repeat catheter ablation according to current European Society of Cardiology (ESC) AF management guidelines; Continuous oral anticoagulation with a vitamin K antagonist or non-vitamin K oral anticoagulant (NOAC) for ≥ 4 weeks prior to the ablation, or transoesophageal echocardiography (TEE) and/or cardiac computed tomography (CT) within 48 hours before the procedure excluding LA thrombus; Age ≥ 18 years at the time of informed consent; Written informed consent obtained prior to any study-related procedures.
Exclusion: Previous LA surgery; > 1 prior LA ablation; AF due to reversible causes (e.g. hyperthyroidism, cardiothoracic surgery); Prior mitral valve surgery; Ongoing triple antithrombotic/anticoagulation therapy; Myocardial infarction during the 3-month period preceding the consent date; Cardiac surgery during the 3-month interval preceding the informed consent date or scheduled cardiac surgery/transcatheter aortic valve implantation procedure; Significant congenital heart defect (including atrial septal defects or PV abnormalities but not including a patent foramen ovale); New York Heart Association (NYHA) class III or IV congestive heart failure; Cerebral ischemic event (stroke or TIA) during the 6-month interval preceding the informed consent date; Ongoing systemic infections; Cardiac amyloidosis; Left ventricular ejection fraction (LVEF) <35%; Significant chronic kidney disease (eGFR <30 ml/min); Patients in persistent AF lasting >3 years; Pregnancy (to exclude pregnancy a blood test (HCG) is performed in women < 50 years before inclusion); LA ablation outside of the PVs in the first LA ablation; LA diameter >60 mm in the parasternal long axis; Pre-existing PV stenosis or PV stent; Pre-existing hemidiaphragmatic paralysis; Contraindication to anticoagulation or radiocontrast materials; Severe mitral regurgitation or moderate/severe mitral stenosis; Hypertrophic cardiomyopathy or left septal wall thickness >1.5 cm; Uncontrolled hyperthyroidism; Life expectancy less than one year per physician opinion; Currently participating in any other clinical trial, which may confound the results of this trial; Unwilling or unable to comply fully with the study procedures and FU.